gptkbp:instanceOf
|
gptkb:drug
small molecule
|
gptkbp:approvalYear
|
2020
|
gptkbp:approvedBy
|
gptkb:FDA
|
gptkbp:ATCCode
|
L01XX71
|
gptkbp:brand
|
gptkb:Tazverik
|
gptkbp:CASNumber
|
1403254-99-8
|
gptkbp:chemicalClass
|
gptkb:pyridone
benzamide
|
gptkbp:developer
|
gptkb:Epizyme,_Inc.
|
gptkbp:hasMolecularFormula
|
C34H44N4O4
|
gptkbp:hasSMILES
|
CC1=CC(=O)N(C2=CC=CC=C12)C3=CC=C(C=C3)NC(=O)C4=CC=C(C=C4)C(C)(C)C5=CC=C(C=C5)C(C)(C)C
|
https://www.w3.org/2000/01/rdf-schema#label
|
tazemetostat
|
gptkbp:KEGGID
|
D10813
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:mechanismOfAction
|
EZH2 inhibitor
|
gptkbp:molecularWeight
|
572.74 g/mol
|
gptkbp:pregnancyCategory
|
Not recommended
|
gptkbp:PubChem_CID
|
gptkb:DB12983
gptkb:CHEMBL3137347
46209410
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
constipation
fatigue
cough
decreased appetite
pyrexia
|
gptkbp:synonym
|
gptkb:E7438
gptkb:EPZ-6438
|
gptkbp:target
|
gptkb:EZH2
gptkb:EZH1
|
gptkbp:UNII
|
6J8OL8451O
|
gptkbp:usedFor
|
epithelioid sarcoma
follicular lymphoma
|
gptkbp:bfsParent
|
gptkb:EZH2
|
gptkbp:bfsLayer
|
7
|